The European Union has formally adopted its long-awaited New Genomic Techniques (NGT) Regulation, marking one of the most significant developments in European agricultural biotechnology in recent years. The new legal framework establishes a dedicated regulatory regime for plants developed through certain genome-editing technologies and aims to facilitate innovation while maintaining existing safeguards for products considered to present higher regulatory concerns.

The legislation follows several years of scientific assessments, policy discussions and legislative negotiations. It reflects the EU’s effort to modernise its regulatory framework for plant breeding technologies while maintaining a distinction between different categories of genome-edited plants.

A New Two-Tier Regulatory System

One of the key features of the Regulation is the introduction of two separate regulatory categories for plants developed using New Genomic Techniques.

NGT-1 Plants

Plants classified as NGT-1 are those whose genetic modifications could also occur naturally or be obtained through conventional breeding methods.

For these plants, the Regulation introduces a significantly simplified regulatory pathway. Subject to meeting the applicable eligibility criteria, NGT-1 plants will:

  • benefit from a simplified verification procedure;
  • no longer be subject to the full GMO authorisation process;
  • be exempt from GMO-specific product labelling requirements; and
  • gain faster access to the European market.

This approach seeks to reduce administrative burdens for plant breeders while supporting the development of improved crop varieties.

NGT-2 Plants

Plants that do not meet the NGT-1 criteria will fall within the NGT-2 category.

These plants will continue to be regulated largely under the existing GMO framework, including requirements relating to:

  • pre-market authorisation;
  • traceability;
  • labelling; and
  • risk assessment.

Accordingly, the new Regulation does not replace the EU’s GMO legislation but instead creates a differentiated framework based on the characteristics of the resulting plant.

Greater Transparency for Patent-Protected Plants

In addition to changes affecting regulatory approval, the Regulation introduces new transparency measures concerning intellectual property.

Where patents relate to NGT plants, applicants and right holders will be required to provide specific information regarding patent protection. These measures are intended to improve transparency within the breeding sector and assist stakeholders in identifying relevant intellectual property rights.

The interaction between patent protection, plant breeding activities and access to genetic material is expected to remain an important topic as the new framework is implemented.

Supporting Innovation in Plant Breeding

The Regulation is intended to facilitate the development of plant varieties with characteristics such as:

  • improved resistance to plant diseases;
  • greater tolerance to drought and other environmental stresses;
  • enhanced climate resilience;
  • improved resource efficiency; and
  • other traits contributing to sustainable agricultural production.

By introducing a more proportionate regulatory approach for certain genome-edited plants, the EU aims to encourage innovation while maintaining appropriate regulatory oversight.

Entry into Application

The Regulation represents a major reform of EU biotechnology legislation. However, its practical implementation will require the adoption of secondary legislation and administrative procedures before the new system becomes fully operational.

Businesses, plant breeders, research institutions and intellectual property owners developing genome-edited products should begin evaluating how their products may be classified under the new framework and consider the potential implications for both regulatory and IP strategies.

Conclusion

The adoption of the New Genomic Techniques Regulation establishes a new legal framework for genome-edited plants within the European Union. By distinguishing between different categories of genome-edited plants, the Regulation introduces a more tailored regulatory approach while maintaining oversight for products requiring additional assessment.

For companies active in biotechnology, plant breeding and agricultural innovation, the new framework is expected to become an important component of future product development and market access strategies within the European Union.